⌘K
Loading ticker…
As of 2026-08-24, AbCellera Biologics Inc. Common Shares (ABCL) has a 3-month relative strength percentile of 98 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 90. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.1%, relative volume 0.65×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ABCL is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 45.0% / 121.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ABCL is held by 5 ETFs as of May 2026. Top owner: ONEQ at 0.01% weight, $831K notional. Top 3 carry $1M.
Held by 11 ETFs · $12M across latest filings · largest weight 1.06% (IDNA).
Top 5 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| ONEQ | 0.01% | $831K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $400K | — |
| AVSC | 0.01% | $246K | — |
| IBBQ | 0.15% | $100K | +0.07 pp |
| BIB | 0.09% | $69K | +0.04 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ABCL Jan avg: 1.87% median: 4.90% win: 75% σ: 8.43% n: 4 2022-04-12 → 2026-07-31 | ABCL Feb avg: -10.03% median: -9.81% win: 0% σ: 10.78% n: 4 2022-04-12 → 2026-07-31 | ABCL Mar avg: -9.40% median: -10.27% win: 0% σ: 4.37% n: 4 2022-04-12 → 2026-07-31 | ABCL Apr avg: -0.76% median: -10.08% win: 40% σ: 17.27% n: 5 2022-04-12 → 2026-07-31 | ABCL May avg: 6.39% median: 2.80% win: 60% σ: 25.97% n: 5 2022-04-12 → 2026-07-31 | ABCL Jun avg: 21.00% median: 27.23% win: 60% σ: 37.56% n: 5 2022-04-12 → 2026-07-31 | ABCL Jul avg: 5.42% median: 10.13% win: 60% σ: 22.57% n: 5 2022-04-12 → 2026-07-31 | ABCL Aug avg: -12.77% median: -13.98% win: 25% σ: 15.93% n: 4 2022-04-12 → 2026-07-31 (current) | ABCL Sep avg: -0.27% median: -2.92% win: 50% σ: 15.42% n: 4 2022-04-12 → 2026-07-31 | ABCL Oct avg: 6.08% median: 7.67% win: 75% σ: 12.68% n: 4 2022-04-12 → 2026-07-31 | ABCL Nov avg: 0.21% median: 9.52% win: 75% σ: 22.14% n: 4 2022-04-12 → 2026-07-31 | ABCL Dec avg: -2.76% median: -5.48% win: 25% σ: 17.79% n: 4 2022-04-12 → 2026-07-31 |